REFERENCES
1. Akhmanova A, Steinmetz MO. Control of microtubule organization and dynamics: two ends in the limelight. Nat Rev Mol Cell Biol 2015;16:711-26.
2. Yang CH, Horwitz SB. Taxol®: the first microtubule stabilizing agent. Int J Mol Sci 2017;18:E1733.
3. Lewis SA, Lee MG, Cowan NJ. Five mouse tubulin isotypes and their regulated expression during development. J Cell Biol 1985;101:852-61.
4. Denoulet P, Eddé B, Gros F. Differential expression of several neurospecific beta-tubulin mRNAs in the mouse brain during development. Gene 1986;50:289-97.
5. Yu I, Garnham CP, Roll-Mecak A. Writing and Reading the Tubulin Code. J Biol Chem 2015;290:17163-72.
6. Janke C, Montagnac G. Causes and consequences of microtubule acetylation. Curr Biol 2017;27:R1287-92.
7. Hammond JW, Cai D, Verhey KJ. Tubulin modifications and their cellular functions. Curr Opin Cell Biol 2008;20:71-6.
9. Westermann S, Weber K. Post-translational modifications regulate microtubule function. Nat Rev Mol Cell Biol 2003;4:938-47.
10. Cambray-Deakin MA, Burgoyne RD. Posttranslational modifications of α-tubulin: acetylated and detyrosinated forms in axons of rat cerebellum. J Cell Biol 1987;104:1569-74.
11. Paturle L, Wehland J, Margolis RL, Job D. Complete separation of tyrosinated, detyrosinated, and nontyrosinatable brain tubulin subpopulations using affinity chromatography. Biochemistry 1989;28:2698-704.
12. Eddé B, Rossier J, Le Caer JP, Desbruyères E, Gros F, et al. Posttranslational glutamylation of alpha-tubulin. Science 1990;247:83-5.
13. Rogowski K, van Dijk J, Magiera MM, Bosc C, Deloulme JC, et al. A family of protein-deglutamylating enzymes associated with neurodegeneration. Cell 2010;143:564-78.
14. Erck C, Peris L, Andrieux A, Meissirel C, Gruber AD, et al. A vital role of tubulin-tyrosine-ligase for neuronal organization. Proc Natl Acad Sci USA 2005;102:7853-8.
15. Ikegami K, Heier RL, Taruishi M, Takagi H, Mukai M, et al. Loss of β-tubulin polyglutamylation in ROSA22 mice is associated with abnormal targeting of KIF1A and modulated synaptic function. Proc Natl Acad Sci USA 2007;104:3213-8.
16. Farache D, Emorine L, Haren L, Merdes A. Assembly and regulation of γ-tubulin complexes. Open Biol 2018;8:170266.
17. Caplow M, Fee L. Dissociation of the tubulin dimer is extremely slow, thermodynamically very unfavorable, and reversible in the absence of an energy source. Mol Biol Cell 2002;13:2120-31.
18. Hiller G, Weber K. Radioimmunoassay for tubulin: a quantitative comparison of the tubulin content of different established tissue culture cells and tissues. Cell 1978;14:795-804.
20. Luduena RF. A hypothesis on the origin and evolution of tubulin. Int Rev Cell Mol Biol 2013;302:41-185.
21. Fees CP, Moore JK. Regulation of microtubule dynamic instability by the carboxy-terminal tail of β-tubulin. Life Sci Alliance 2018;1:e201800054.
22. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002;2:1-17.
23. Inoué S, Sato H. Cell motility by labile association of molecules. The nature of mitotic spindle fibers and their role in chromosome movement. J Gen Physiol 1967;50:259-92.
25. Cassimeris L. Accessory protein regulation of microtubule dynamics throughout the cell cycle. Curr Opin Cell Biol 1999;11:134-41.
26. Kreis T, Vale R. Guidebook to the cytoskeleton and motor proteins. London/New York: Oxford Univ. Press; 1999.
27. Ohi R, Zanic M. Ahead of the curve: new insights into microtubule dynamics. F1000Res 2016;5:314-22.
29. Pepperkok R, Bre MH, Davoust J, Kreis TE. Microtubules are stabilized in confluent epithelial cells but not in fibroblasts. J Cell Biol 1990;111:3003-12.
30. Saxton WM, Stemple DL, Leslie RJ, Salmon ED, Zavortink M, et al. Tubulin dynamics in cultured mammalian cells. J Cell Biol 1984;99:2175-86.
31. Rusan NM, Fagerstrom CJ, Yvon AM, Wadsworth P. Cell cycle-dependent changes in microtubule dynamics in living cells expressing green fluorescent protein-α tubulin. Mol Biol Cell 2001;12:971-80.
32. Correia JJ, Lobert S. Physiochemical aspects of tubulin-interacting antimitotic drugs. Current Pharmaceutical Design 2001;7:1213-28.
33. Visconti R, Grieco D. Fighting tubulin-targeting anticancer drug toxicity and resistance. Endocr Relat Cancer 2017;24:T107-17.
34. Tame MA, Manjón AG, Belokhvostova D, Raaijmakers JA, Medema RH. TUBB3 overexpression has a negligible effect on the sensitivity to taxol in cultured cell lines. Oncotarget 2017;8:71536-47.
35. Alkadi H, Khubeiz MJ, Jbeily R. Colchicine: a review on chemical structure and clinical usage. Infect Disord Drug Targets 2018;18:105-21.
36. Rao CV, Kurkjian CD, Yamada HY. Mitosis-targeting natural compounds for cancer prevention and therapy. Curr Drug Targets 2012;13:1820-30.
37. Downing KH, Nogales E. New insights into microtubule structure and function from the atomic model of tubulin. Eur Biophys J 1998;27:431-6.
38. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010;9:790-803.
40. Downing KH. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol 2000;16:89-111.
41. Silverman JA, Deitcher SR. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol 2013;71:555-64.
42. Silvestri R. New prospects for vinblastine analogues as anticancer agents. J Med Chem 2013;56:625-7.
43. Carlson RO. New tubulin targeting agents currently in clinical development. Expert Opin Invest Drugs 2008;17:707-22.
44. Blume E. Investigators Seek to Increase Taxol Supply. J National Cancer Institute 1989;81:1122-3.
46. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993;32:2747-55.
47. Manfredi JJ, Parness J, Horwitz SB. Taxol binds to cellular microtubules. J Cell Biol 1982;94:688-96.
48. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003;3:193-203.
49. Field JJ, Pera B, Calvo E, Canales A, Zurwerra D, et al. Zampanolide, a potent new microtubule-stabilizing agent, covalently reacts with the taxane luminal site in tubulin α,β-heterodimers and microtubules. Chem Biol 2012;19:686-98.
50. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7.
51. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of taxol resistance related to microtubules. Oncogene 2003;22:7280-95.
52. Diaz JF, Valpuesta JM, Chacon P, Diakun G, Andreu JM. Changes in microtubule protofilament number induced by Taxol binding to an easily accessible site. Internal microtubule dynamics. J Biol Chem 1998;273:33803-10.
54. Ferlini C, Cicchillitti L, Raspaglio G, Bartollino S, Cimitan S, et al. Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res 2009;69:6906-14.
55. Ganguly A, Yang H, Cabral F. Paclitaxel dependent cell lines reveal a novel drug activity. Mol Cancer Ther 2010;9:2914-23.
56. Komlodi-Pasztor E, Sackett D, Fojo AT. Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res 2012;18:51-63.
57. Bogdan C, Ding A. Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. J Leukoc Biol 1992;52:119-21.
58. Bocci G, Di Paolo A, Danesi R. The pharmacological bases of the antiangiogenic activity of paclitaxel. Angiogenesis 2013;16:481-92.
61. Höfle G, Bedorf N, Steinmetz H, Schemburg D, Gerth K, et al. Epothilone A and B - novel 16-membered macrolides and cytotoxic activity: isolation, crystal structure, and conformation in solution. Angew Chem Int Ed Engl 1996;35:1567-9.
62. Krause W, Klar U. Differences and similarities of epothilones. Current Cancer Therapy Reviews 2011;7:10-36.
63. Winsel S, Berlin A. .
64. Klar U, Hoffmann J, Giurescu M. Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate. Expert Opin Investig Drugs 2008;17:1735-48.
65. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, et al. The binding mode of epothilone A on α, β-tubulin by electron crystallography. Science 2004;305:866-9.
66. Bode CJ, Gupta ML, Reiff EA, Suprenant KA, Georg GI, et al. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 2002;41:3870-4.
67. Yardley DA. Drug resistance and the role of combination chemotherapy in improving patient outcomes. Int J Breast Cancer 2013;2013:137414.
68. Cortes J, Vidal M. Beyond taxanes: the next generation of microtubule-targeting Agents. Breast Cancer Res Treat 2012;133:821-30.
69. Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull 2017;7:339-48.
70. Mansoori B, Mohammadi A, Shirjang S, Baradaran B. MicroRNAs in the Diagnosis and Treatment of Cancer. Immunol Invest 2017;46:880-97.
72. Cree IA, Charlton P. Molecular chess? Hallmarks of anti-cancer drug resistance. BMC Cancer 2017;17:10-8.
73. Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, et al. Cancer cell adaptation to chemotherapy. BMC Cancer 2005;5:78-94.
74. BC Cancer. Available from: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Vinblastine_monograph_1Feb2015.pdf. [Last accessed on 1 Mar 2019].
75. BC Cancer. Available from: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Vincristine_monograph_1Mar08.pdf. [Last accessed on 1 Mar 2019].
76. Vindesine. Available from: https://hemonc.org/w/images/3/33/Vindesine.pdf. [Last accessed on 26 Feb 2019].
77. BC Cancer. Available from: http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Vinorelbine%20monograph_1Feb2015.pdf. [Last accessed on 1 Mar 2019].
78. AusPAR: Vinflunine ditartrate. Australian Public Assessment Report, 2011. Available from: https://www.tga.gov.au/auspar/auspar-vinflunine-ditartrate. [Last accessed on 26 Feb 2019].
79. FDA Label. Available from: https://www.accessdata.fda.gov/drugsatfda/label. [Last accessed on 28 Feb 2019].
80. Kelly KR, Zollinger M, Lozac’h F, Tan E, Mita A, et al. Metabolism of patupilone in patients with advanced solid tumor malignancies. Invest New Drugs 2013;31:605-15.
81. European Medicines Agency. Withdrawal assessment report for Ixempra. Available from: https://www.ema.europa.eu/documents/withdrawal-report/withdrawal-assessment-report-ixempra_en.pdf. [Last accessed on 28 Feb 2019].
82. Konner J, Grisham RN, Park J, O’Connor OA, Cropp G, et al. Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma. Invest New Drugs 2012;30:2294-302.
83. Lam ET, Goel S, Schaaf LJ, Cropp GF, Hannah AL, et al. Phase I dose escalation study of KOS 1584, a novel epothilone, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2012;69:523-31.
84. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004;5:243-72.
85. Silverman JA, Reynolds L, Deitcher SR. Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia. J Clin Pharmacol 2013;53:1139-45.
86. Ohishi Y, Oda Y, Basaki Y, Kobayashi H, Wake N, et al. Expression of β-tubulin isotypes in human primary ovarian carcinoma. Gynecol Oncol 2007;105:586-92.
87. Izutsu N, Maesawa C, Shibazaki M, Oikawa H, Shoji T, et al. Epigenetic modification is involved in aberrant expression of class III β-tubulin, TUBB3, in ovarian cancer cells. Int J Oncol 2008;32:1227-35.
88. Du J, Li B, Fang Y, Liu Y, Wang Y, et al. Overexpression of class III beta-tubulin, sox2, and nuclear survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer. BMC Cancer 2015;15:536-47.
89. Roque DM, Bellone S, English DP, Buza N, Cocco E, et al. Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer 2013;119:2582-92.
90. Ullah MF, Aatif M. The footprints of cancer development: cancer biomarkers. Cancer Treat Rev 2009;35:193-200.
91. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
92. Safa AR. Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. Curr Med Chem Anticancer Agents 2004;4:1-17.
93. Manzoor S, Bilal A, Khan S, Ullah R, Iftikhar S, et al. Identification and characterization of SSE15206, a microtubule depolymerizing agent that overcomes multidrug resistance. Sci Rep 2018;8:3305.
94. Fojo T, Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 2007;18:3-8.
95. Su DS, Balog A, Meng D, Bertinato P, Danishefsky SJ, et al. Structure-activity Relationships of the epothilones and the first in vivo comparison with paclitaxel. Angew Chem Int Ed Engl 1997;36:2093-6.
96. Chou TC, O’Connor OA, Tong WP, Guan Y, Zhang ZG, et al. The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc Natl Acad Sci USA 2001;98:8113-8.
97. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, et al. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993:55-61.
98. Jachez B, Nordmann R, Loor F. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. J Natl Cancer Inst 1993;85:478-83.
99. Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993;81:490-5.
100. Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 1995;75:815-20.
101. Koushik OS, Rao YV, Kumar P, Karthikeyan R. Nano drug delivery systems to overcome cancer drug resistance - a review. J Nanomed Nanotechnol 2016;7:378.
102. Cisternino S, Bourasset F, Archimbaud Y, Semiond D, Sanderink G, et al. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Brit J Pharmacol 2003;138:1367-75.
103. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, et al. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res 2009;69:178-84.
104. Lin JH, Yamazaki M. Clinical relevance of P-Glycoprotein in drug therapy. Drug Metab Rev 2003;35:417-54.
105. Guo HQ, Zhang GN, Wang YJ, Zhang YK, Sodani K, et al. β-Elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by theABCB1 transporter. Oncology Reports 2014;31:858-66.
106. Loe DW, Almquist KC, Deeley RG, Cole SP. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem 1996;271:9675-82.
107. Kitazono M, Sumizawa T, Takebayashi Y, Chen ZS, Furukawa T, et al. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Nat Cancer Inst 1999;91:1647-53.
108. Izquierdo MA, van der Zee AG, Vermorken J, van der Valk P, Belien JA, et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995;87:1230-6.
109. Parker AL, Teo WS, McCarroll JA, Kavallaris M. An emerging role for tubulin isotypes in modulating cancer biology and chemotherapy resistance. Int J Mol Sci 2017;18:1434-58.
110. Vilmar A, Garcia-Foncillas J, Huarriz M, Santoni-Rugiu E, Sorensen JB. RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC. Lung Cancer 2012;75:306-12.
111. Iseri OD, Kars MD, Gunduz U. Drug resistant MCF-7 cells have altered expression levels of beta-tubulin isotypes and mutations in TUBB gene. Int J Hematol Oncol 2010;2:75-83.
112. Freedman H, Huzil JT, Luchko T, Luduena RF, Tuszynski JA. Identification and characterization of an intermediate taxol binding site within microtubule nanopores and a mechanism for tubulin isotype binding selectivity. J Chem Inf Model 2009;49:424-36.
113. Kavallaris M, Kuo DYS, Burkhart CA, Regl DL, Norris MD, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 1997;100:1282-93.
114. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, et al. Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005;11:298-305.
115. Ferrandina G, Zannoni GF, Martinelli E, Paglia A, Gallotta V, et al. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006;12:2774-9.
116. Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, et al. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009;115:2453-63.
117. De Donato M, Mariani M, Petrella L, Martinelli E, Zannoni GF, et al. Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol 2012;227:1034-41.
118. Roque DM, Buza N, Glasgow M, Bellone S, Bortolomai I, et al. Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Clin Exp Metastasis 2014;31:101-10.
119. Parker AL, Turner N, McCarroll JA, Kavallaris M. βIII-Tubulin alters glucose metabolism and stress response signaling to promote cell survival and proliferation in glucose-starved non-small cell lung cancer cells. Carcinogenesis 2016;37:787-98.
120. Raspaglio G, Filippetti F, Prislei S, Penci R, De Maria I, et al. Hypoxia induces class III β-tubulin gene expression by HIF-1α binding to its 3′ flanking region. Gene 2008;409:100-8.
121. Bordji K, Grandval A, Cuhna-Alves L, Lechapt-Zalcman E, Bernaudin M. Hypoxia-inducible factor-2 (HIF-2), but not HIF-1, is essential for hypoxic induction of class III β-tubulin expression in human glioblastoma cells. FEBS J 2014;281:5220-36.
122. Raspaglio G, De Maria I, Filippetti F, Martinelli E, Zannoni GF, et al. Hur regulates β-tubulin isotype expression in ovarian cancer. Cancer Res 2010;70:5891-900.
123. Patel VP, Chu CT. Decreased SIRT2 activity leads to altered microtubule dynamics in oxidatively-stressed neuronal cells: Implications for Parkinson’s disease. Exp Neurol 2014;257:170-81.
124. Drum BML, Yuan C, Li L, Liu QH, Wordeman L, et al. Oxidative stress decreases microtubule growth and stability in ventricular myocytes. J Mol Cell Cardiol 2016;93:32-43.
125. Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, et al. Expression of ERCC1 and ulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 2009;64:326-33.
126. Karki R, Ferlini C. Class III beta-tubulin, drug resistance, therapeutic approaches in cancers. Atlas Genet Cytogenet Oncol Haematol 2014;18:865-71.
127. Aoki D, Oda Y, Hattori S, Taguchi K, Ohishi Y, et al. Overexpression of class III β-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. Clin Cancer Res 2009;15:1473-80.
128. Wang Y, Sparano JA, Fineberg S, Stead L, Sunkara J, et al. High expression of class III beta-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer. Clin Breast Cancer 2013;13:103-8.
129. Mozzetti S, Iantomasi R, de Maria I, Prislei S, Mariani M, et al. Molecular mechanisms of patupilone resistance. Cancer Res 2008;68:10197-204.
130. Magnani M, Ortuso F, Soro S, Alcaro S, Tramontano A, et al. The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies. FEBS J 2006;273:3301-10.
131. Ferlini C, Raspaglio G, Mozzetti S, Cicchillitti L, Filippetti F, et al. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res 2005;65:2397-405.
132. Ferrandina G, Mariani M, Andreoli M, Shahabi S, Scambia G, et al. Novel Drugs Targeting Microtubules: the Role of Epothilones. Curr Pharm Des 2012;18:2793-803.
133. Kavallaris M, Burkhardt CA, Horwitz SB. Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 1999;80:1020-5.
134. Miyamoto DT, Perlman ZE, Mitchison TJ, Shirasu-Hiza M. Dynamics of the mitotic spindle - potential therapeutic targets. Prog Cell Cycle Res 2003;5:349-60.
135. Kanakkanthara A, Northcote PT, Miller JH. βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells. Mol. Cancer Ther 2012;11:393-404.
136. Gan PP, McCarroll JA, Po’uha ST, Kamath K, Jordan MA, et al. Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol Cancer Ther 2010;9:1339-48.
137. Gan PP, Kavallaris M. Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity. Cancer Res 2008;68:9817-24.
138. Sharbeen G, McCarroll J, Liu J, Youkhana J, Limbri LF, et al. Delineating the role of βIV-tubulins in pancreatic cancer: βIVb-tubulin inhibition sensitizes pancreatic cancer cells to vinca alkaloids. Neoplasia 2016;18:753-64.
139. Narvi E, Jaakkola K, Winsel S, Oetken-Lindholm C, Halonen P, et al. Altered TUBB3 expression contributes to the epothilone response of mitotic cells. Br J Cancer 2013;108:82-90.
140. Bhattacharya R, Cabral F. A ubiquitous beta-tubulin disrupts microtubule assembly and inhibits cell proliferation. Mol Biol Cell 2004;15:3123-31.
141. Hari M, Yang H, Zeng C, Canizales M, Cabral F. Expression of class III β-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskelet 2003;56:45-56.
142. Blade K, Menick DR, Cabral F. Overexpression of class I, II or IVb β-tubulin isotypes in CHO cells is insufficient to confer resistance to paclitaxel. J Cell Sci 1999;112:2213-21.
143. Ranganathan S, McCauley RA, Dexter DW, Hudes GR. Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells. Br J Cancer 2001;85:735-40.
144. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
145. Tsourlakis MC, Weigand P, Grupp K, Kluth M, Steurer S, et al. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion. Am J Pathol 2014;184:609-17.
146. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
147. Sobierajska K, Wieczorek K, Ciszewski WM, Sacewicz-Hofman I, Wawro ME, et al. β-III tubulin modulates the behavior of snail overexpressed during the epithelial-to-mesenchymal transition in colon cancer cells. Biochim Biophys Acta 2016;1863:2221-33.
148. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 2008;1785:96-132.
149. Kavallaris M. Microtubules and resistance to tubulin- tubulin-binding agents. Nat Rev Cancer 2010;10:194-204.
150. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 2005;102:8315-20.
151. Cabral FR, Brady RC, Schibler MJ. A mechanism of cellular resistance to drugs that interfere with microtubule assembly. Ann NY Acad Sci 1986;466:745-56.
152. Cabral F, Barlow SB. Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly. FASEB J 1989;3:1593-9.
153. Minotti AM, Barlow SB, Cabral F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlated with changes in the level of polymerized tubulin. J Biol Chem 1991;266:3987-94.
154. Derry WB, Wilson L, Jordan MA. Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry 1995;34:2203-11.
155. Wilson L, Jordan MA. Microtubule dynamics: taking aim at a moving target. Chem Biol 1995;2:569-73.
156. Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998;10:123-30.
157. Goncalves A, Braguer D, Kamath K, Martello L, Briand C, et al. Resistance to taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci USA 2001;98:11737-41.
158. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, et al. Paclitaxel resistant human ovarian cancer cells have mutant beta- tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272:17118-25.
159. Zhong S, Chen X, Wang D, Zhang X, Shen H, et al. MicroRNA expression profiles of drug-resistance breast cancer cells and their exosomes. Oncotarget 2016;7:19601-9.
160. Fang Y, Xu C, Fu Y. MicroRNA-17-5p induces drug resistance and invasion of ovarian carcinoma cells by targeting PTEN signaling. J Biol Res (Thessalon) 2015;22:12.
161. Hu W, Tan C, He Y, Zhang G, Xu Y, et al. Functional miRNAs in breast cancer drug resistance. Onco Targets Ther 2018;11:1529-41.
162. Zhu X, Li Y, Xie C, Yin X, Liu Y, et al. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer 2014;135:1286-96.
163. Li H, Zhang P, Sun X, Sun Y, Shi C, et al. MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. Int J Oncol 2015;47:1379-92.
164. Naghizadeh S, Mansoori B, Mohammadi A, Sakhinia E, Baradaran B. Gene silencing strategies in cancer therapy: an update for drug resistance. Curr Med Chem 2018; doi: 10.2174/0929867325666180403141554.
166. de Vree JM, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA 1998;95:282-7.
167. Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev 2012;38:890-903.
168. Kienitz A, Vogel C, Morales I, Muller R, Bastians H. Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol. Oncogene 2005;24:4301-10.
169. Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 2003;116:2987-98.
170. Chen X, Yeung T, Wang W. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem Biophys Res Commun 2000;277:757-63.
171. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996;2:72-9.
172. Shitashige M, Toi M, Yano T, Shibata M, Matsuo Y, et al. Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2. J Biochem 2001;130:741-8.
174. Genovese I, Ilari A, Battista T, Chiarini V, Fazi F, et al. Molecular bases of Sorcin-dependent resistance to chemotherapeutic agents. Cancer Drug Resists 2018;1:164-80.
175. Hu Y, Li S, Yang M, Yan C, Fan D, et al. Sorcin silencing inhibits epithelial-to-mesenchymal transition and suppresses breast cancer metastasis in vivo. Breast Cancer Res Treat 2014;143:287-99.
176. Lalioti VS, Ilari A, O’Connell DJ, Poser E, Sandoval IV, et al. Sorcin links calcium signaling to vesicle trafficking, regulates Pololike kinase 1 and is necessary for mitosis. PLoS One 2014;9:e85438.
177. Maddalena F, Sisinni L, Lettini G, Condelli V, Matassa DS, et al. Resistance to paclitxel in breast carcinoma cells requires a quality control of mitochondrial antiapoptotic proteins by TRAP1. Mol Oncol 2013;7:895-906.
178. Maddalena F, Laudiero G, Piscazzi A, Secondo A, Scorziello A, et al. Sorcin induces a drug-resistant phenotype in human colorectal cancer by modulating Ca(2+) homeostasis. Cancer Res 2011;71:7659-69.
179. Colotti G, Poser E, Fiorillo A, Genovese I, Chiarini V, et al. Sorcin, a calcium binding protein involved in the multidrug resistance mechanisms in cancer cells. Molecules 2014;19:13976-89.
180. Gao Y, Li W, Liu X, Gao F, Zhao X. Reversing effect and mechanism of soluble resistance-related calcium-binding protein on multidrug resistance in human lung cancer A549/DDP cells. Mol Med Rep 2015;11:2118-24.
181. Hu Y, Cheng X, Li S, Zhou Y, Wang J, et al. Inhibition of sorcin reverses multidrug resistance of K562/A02 cells and MCF-7/A02 cells via regulating apoptosis-related proteins. Cancer Chemother Pharmacol 2013;72:789-98.
182. Gong J, Zhou Y, Liu D, Huo J. F-box proteins involved in cancer-associated drug resistance (Review). Oncol Lett 2018;15:8891-900.
183. Hershko DD. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer 2008;112:1415-24.
184. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011;471:110-4.
185. Yokobori T, Mimori K, Iwatsuki M, Ishii H, Onoyama I, et al. p53-altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res 2009;69:3788-94.
186. Yeh CH, Bellon M, Nicot C. FBXW7: a critical tumor suppressor of human cancers. Molecular Cancer 2018;17:115.
187. Xu Y, Sengupta T, Kukreja L, Minella AC. MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7. J Biol Chem 2010;285:34439-46.
188. Mozzetti S, Martinelli E, Raspaglio G, Prislei S, De Donato M, et al. Gli family transcription factors are drivers of patupilone resistance inovarian cancer. Biochem Pharmacol 2012;84:1409-18.
189. Katayama K, Noguchi K, Sugimoto Y. FBXO15 regulates P-glycoprotein/ABCB1 expression through the ubiquitin-proteasome pathway in cancer cells. Cancer Sci 2013;104:694-702.
190. Kreitzburg KM, van Waardenburg RCAM, Yoon KJ. Sphingolipid metabolism and drug resistance in ovarian cancer. Cancer Drug Resist 2018;1:181-97.
191. Dobbin ZC, Katre AA, Steg AD, Erickson BK, Shah MM, et al. Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer. Oncotarget 2014;5:8750-64.
192. Swanton C, Marani M, Pardo O, Warne PH, Kelly G, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007;11:498-512.
193. Prinetti A, Millimaggi D, D’Ascenzo S, Clarkson M, Bettiga A, et al. Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells. Biochem J 2006;395:311-8.
194. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. PNAS 2003;100:3983-8.
195. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-8.
196. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-8.
197. Liu FS. Mechanisms of chemotherapeutic drug resistance in cancer therapy - a quick review. Taiwan J Obstet Gynecol 2009;48:239-44.
198. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007;317:37.
199. Mansoori M, Madjd Z, Janani L, Rasti A. Circulating cancer stem cell markers in breast carcinomas: a systematic review protocol. Syst Rev 2017;6:262.
200. Yu Z, Pestellc TG, Lisantic MP, Pestellb RG. Cancer stem cells. Int J Biochem Cell Biol 2012;44:2144-51.
201. Lou H, Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007;26:1357-60.
202. Bourguignon LYW, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker, Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 2008;283:17635-51.
203. Ruxrungtham K, Sirivichayakul S, Buranapraditkun S, Krause W. Alemtuzumab-induced elimination of HIV-1-infected immune cells. J Virus Erad 2016;2:12-8.
204. Hennenfent KL, Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol 2006;17:735-49.
205. Ma P, Mumper RJ. Paclitaxel nano-delivery systems: a comprehensive review. Nanomed Nanotechnol 2013;4:1000164.
206. Ojima I, Lichtenthal B, Lee S, Wang C, Wang X. Taxane anticancer agents: a patent perspective. Expert Opin Ther Pat 2016;26:1-20.
207. Régina A, Demeule M, Ché C, Lavallée I, Poirier J, et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 2008;155:185-97.
208. Mooberry SL, Tien G, Hernandez AH, Plubrukarn A, Davidson BS. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. Cancer Res 1999;59:653-60.
209. Churchill CDM, Klobukowski M, Tuscynski JA. Analysis of the binding mode of laulimalide to microtubules: establishing a laulimalide-tubulin pharmacophore. J Biomol Struct Dyn 2015;34:1-35.
210. Bennett MJ, Chan GK, Rattner JB, David C, Schriemer DC. Low-dose laulimalide represents a novel molecular probe for investigating microtubule organization. Cell Cycle 2012;11:3045-54.
211. Pryor DE, O’Brate A, Bilcer G, Díaz JF, Wang Y, et al. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry 2002;41:9109-15.
212. Hamel E, Day BW, Miller JH, Jung MK, Northcote PT, et al. Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol 2006;70:1555-64.
213. Kanakkanthara A, Northcote PT, Miller JH. Peloruside A: a lead non-taxoid-site microtubule-stabilizing agent with potential activity against cancer, neurodegeneration, and autoimmune disease. Nat Prod Rep 2016;33:549-61.
214. Ganguly A, Cabral F, Yang H, Patel KD. Peloruside A is a microtubule-stabilizing agent with exceptional anti-migratory properties in human endothelial cells. Oncoscience 2015;2:585-95.
215. Gunasekera SP, Gunasekera M, Longley RE, Schulte GK. Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge Discodermia dissoluta. J Org Chem 1990;55:4912-5.
216. Martello LA, McDaid HM, Regl DL, Yang CPH, Meng D, et al. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin Cancer Res 2000;6:1978-87.
217. Mita A, Lockhart AC, Chen TL, Bochinski K, Curtright J, et al. A phase I pharmacokinetic (PK) trial of XAA296A (Discodermolide) administered every 3 wks to adult patients with advanced solid malignancies. J Clin Oncol 2004;22:2025.
218. Tanaka J, Higa T. Zampanolide, a new cytotoxic macrolide from a marine sponge. Tetrahedron Lett 1996;37:5535-8.
219. Field JJ, Pera B, Calvo E, Canales A, Zurwerra D, et al. Zampanolide, a potent new microtubule stabilizing agent, covalently reacts with the taxane luminal site in both tubulin α,β-heterodimers and microtubules. Chem Biol 2012;19:686-98.
220. Chen QH, Kingston DG. Zampanolide and dactylolide: cytotoxic tubulin-assembly agents and promising anticancer leads. Nat Prod Rep 2014;31:1202-26.
221. Field JJ, Northcote PT, Paterson I, Altmann KH, Díaz JF, et al. Zampanolide, a microtubule-stabilizing agent, is active in resistant cancer cells and inhibits cell migration. Int J Mol Sci 2017;18:E971.
222. Scheuer PJ, Swanholm CE, Madamba LA, Hudgins WR. The constituents of Tacca leontopetaloides. Lloydia 1963;26:133-40.
223. Tinley TL, Randall-Hlubek DA, Leal RM, Jackson EM, Cessac JW, et al. Taccalonolides E and A: plant-derived steroids with microtubule-stabilizing activity. Cancer Res 2003;63:3211-20.
224. Lia J, Risinger AL, Mooberry SL. Taccalonolide microtubule stabilizers. Bioorg Med Chem 2014;22:5091-6.
225. Wang Y, Yu Y, Li GB, Li SA, Wu C, et al. Mechanism of microtubule stabilization by taccalonolide AJ. Nat Commun 2017;8:15787.
226. Martín MJ, Coello L, Fernández R, Reyes F, Rodríguez A, et al. Isolation and first total synthesis of PM050489 and PM060184, two new marine anticancer compounds. J Am Chem Soc 2013;135:10164-71.
227. Pera B, Barasoain I, Pantazopoulou A, Canales A, Matesanz R, et al. New interfacial microtubule inhibitors of marine origin, PM050489/PM060184, with potent antitumor activity and a distinct mechanism. ACS Chem Biol 2013;8:2084-94.
